

FOI Request Local Treatment Guidelines Non-Small Cell Lung Cancer

Question 1

<p>Does Salisbury NHS Foundation Trust have any local treatment guidelines/pathways/protocols/algorithms for the treatment of non-small cell lung cancer?</p>	<p>Yes</p>	<p><i>We benchmark ourselves against the Lung Timed Pathway for all Lung Cancer diagnostics and the 31d Decision to treat target / 62d First definitive treatment targets.</i></p> <p><i>Please see below:</i></p>

Question 2

<p>Does Salisbury NHS Foundation Trust have protocols for the use of the following targeted drug therapies in the treatment of non-small cell lung cancer?</p>		
Sotorasib (Lumykras)	Yes	No
	<i>If yes please see question 3</i>	
Entrectinib (Rozlytrek)	Yes	No
Larotrectinib (Vitrakvi)	Yes	No
Dabrafenib (Tafinlar)	Yes	No
Trametinib (Mekinist)	Yes	No
Capmatinib (Tabrecta)	Yes	No
Tepotinib (Tepmetko)	Yes	No
Bevacizumab (Avastin)	Yes	No
Ramucirumab (Cyramza)	Yes	No
Atezolizumab (Tecentriq)	Yes	No
Durvalumab (Imfinzi)	Yes	No
Cemiplimab- (Libtayo)	Yes	No
Nivolumab (Opdivo)	Yes	No

Pembrolizumab (Keytruda)	Yes	No
Ipilimumab (Yervoy)	Yes	No
Afatinib (Giotrif)	Yes	No
Dacomitinib (Vizimpro)	Yes	No
Erlotinib (Tarceva)	Yes	No
Gefitinib (Iressa)	Yes	No
Osimertinib (Tagrisso)	Yes	No
Amivantamab (Rybrevant)	Yes	No
Mobocertinib (Exkivity)	Yes	No
trastuzumab deruxtecan (Enhertu)	Yes	No
Alectinib (Alecensa)	Yes	No
Brigatinib (Alunbrig)	Yes	No
Ceritinib (Zykadia)	Yes	No
Crizotinib (Xalkori)	Yes	No
Lorlatinib (Lorviqua)	Yes	No
Entrectinib (Rozlytrek)	Yes	No
Pralsetinib (Gavreto)	Yes	No
Selpercatinib (Retsevmo)	Yes	No
Nintedanib (Vargatef®)	Yes	No

Question 3

If a local protocol for the use of Sotorasib (Lumykras) for the treatment of non-small cell lung cancer is available please could a copy be provided?

Please see attached document.

Question 4

Does Salisbury NHS Foundation Trust have any local pathways/protocols/guidelines for the use of molecular biomarker testing in diagnosis/treatment of non-small cell lung cancer?		No
	<i>We have no set protocol as such. Molecular markers are requested by the Histopathologist for any sample taken at Salisbury and this decision is made at the MDT. Some of our activity is done at UHS and Molecular is requested by them.</i>	
We use molecular markers to detect genetic variations in tumour samples collected during bronchoscopy, EBUS or other biopsies. The sample is reviewed at MDT and it is decided for molecular markers to be required if the patient is eligible for targeted therapy. The Histopathology consultants will request Molecular testing on samples. We request the following molecular testing – EGFR, ALK, ROS1, PDL1 as well as the following next generation sequencing – including; EGFR, BRAF, KRAS, ALK, ROS1, RET, MET, NTRK1, NTRK2 and NTRK3. Our standard Molecular testing is sent to University Hospital Birmingham. Any NGS testing is sent to Birmingham Women’s and Children’s hospital.		

Question 5

Is Salisbury NHS Foundation Trust part of a Cancer alliance or network, if so which ones?

We are aligned with SWAG – Swindon Wiltshire Avon and Gloucestershire Cancer Alliance – where our funding and reporting goes to.

Our clinical pathways are also aligned with Wessex Cancer Alliance due to geographical location with University Hospital Southampton.